Bcl-2 Expression in Acute Myeloblastic Leukaemia: Relationship with Autonomous Growth and CD34 Antigen Expression

References

• Kerr J. F. R., Wyllie A. H., Currie A. R. Apoptosis: A basic biological phenomenon with wide‐ranging implications in tissue kenetics. Br J Cancer 1972; 26: 239–257
   PubMed Web of Science ®Google Scholar
• Wyllie A. H. Glucocorticoid‐induced thymocyte apoptosis is associated with endogenous nuclease activity. Nature 1980; 284: 555–556
   PubMed Web of Science ®Google Scholar
• Williams G. T., Smith C. A., Spooncer E., Dexter T. M., Taylor D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76–79
   PubMed Web of Science ®Google Scholar
• Rodriguez‐Tarduchy G., Collins M., Lopez‐Rivas A. Regulation of apoptosis in interleukin‐3‐dependent hemopoietic cells by interleukin‐3 and calcium ionophores. EMBO J 1990; 9: 2997–3002
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y., Finger L. R., Junis J., Nowell P. C., Croce C. M. Cloning of the chromosome breakpoint of neo‐plastic B cells with the t(14:18) chromosomal translocation. Science 1984; 226: 1097–1099
   PubMed Web of Science ®Google Scholar
• Pezzella F., Tse A. G. D., Cordell J. L., Pulford K. A. F., Gatter K. C., Mason D. Y. Expression of the bcl‐2 oncogene protein is not specific for the t(14; 18) chromosomal translocation. Am J Pathol 1990; 137: 225–232
   PubMed Web of Science ®Google Scholar
• Zutter M., Hockenbery D., Silverman G. A., Korsmeyer S. J. Immunolocalisation of the bcl‐2 protein within haemopoietic neoplasms. Blood 1991; 81: 3091–3096
   Google Scholar
• Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J. bcl‐2 protein is topographically restricted in tissues characterized by apoptotic cell death. PNAS USA 1991; 88: 6961–6965
   PubMed Web of Science ®Google Scholar
• Hockenbery D., Nunez G., Milliman C., Schreiber R. D., Korsmeyer S. J. bcl‐2 is an inner mitochondria1 membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Chen‐Levy Z., Clearly M. L. Membrane topology of the bcl‐2 proto‐oncogene protein demonstrated in vivo. J Biol Chem 1990; 265: 4929–4933
   PubMed Web of Science ®Google Scholar
• Jacobson M. D., Burnett J. F., King M. D., Miyashita T., Reed J. C., Raff M. C. Bcl‐2 blocks apoptosis in cells lacking mitochondria. Nature 1993; 361: 365–369
   PubMed Web of Science ®Google Scholar
• Monaghan P., Robertson G., Amos T. A. S., Dyer M. J. S., Mason D. Y., Graves M. F. Ultrastructural localisation of bcl‐2 protein. J Histochem Cytochem 1992; 40: 1819–1825
   PubMed Web of Science ®Google Scholar
• Boise L. H., Gonzalez‐Garcia M., Postema C. E., et al. bcl‐x, a bcl‐2–related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. bcl‐2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Yin X. ‐M., Oltvai Z. N., Korsmeyer S. J. BHI and BH2 domains of bcl‐2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321–323
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J., Shutter J. R., Veis D. J., Merry D. E., Oltvai Z. N. bcl‐2/Bax: a rheostat that regulates an anti‐oxidant pathway and cell death. Seminars in Cancer biology 1993; 4: 327–332
   PubMed Web of Science ®Google Scholar
• Delia D., Aiello A., Soligo D., et al. bcl‐2 proto‐oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291–1298
   PubMed Web of Science ®Google Scholar
• Nunez G., London L., Hockenbery D., Alexander M., McKeam J. P., Korsmeyer S. J. Dysregulated bcl‐2 gene expression selectively prolongs the survival of growth‐factor deprived hemopoietic cell lines. J Immunol 1990; 144: 3602–3610
   PubMed Web of Science ®Google Scholar
• Vaux D. L., Cory S., Adams J. M. bcl‐2 gene promotes haemopoietic survival and cooperates with c‐myc to immortalise pre‐B‐cells. Nature 1988; 335: 440–446
   PubMed Web of Science ®Google Scholar
• Bradbury D. A., Russell N. H. Comparative quantitative expression of bcl‐2 by normal and leukaemic myeloid cells. Br J Haematol 1995; 91: 374–379
   PubMed Web of Science ®Google Scholar
• Porwitt‐MacDonald A., Ivory K., Wilkinson S., Wheatley K., Wong L., Janossy G. bcl‐2 protein expression in normal human bone marrow precursors and in acute myelogenous leukaemia. Leukaemia 1995; 9: 1191–1198
   PubMed Web of Science ®Google Scholar
• Park J. R., Bernstein I. D., Hockenbery D. M. Primitive human haematopoietic precursors express bcl‐x but not bcl‐2. Blood 1995; 86: 868–876
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J. C. bcl‐2 oncoprotein blocks chemotherapy‐induced apoptosis in a human leukaemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Campos L., Sabido O., Rouault J. ‐P., Guyotat D. Effects of bcl‐2 antisense oligonucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595–600
   PubMed Web of Science ®Google Scholar
• Keith F. J., Bradbury D. A., Zhu Y. ‐M., Russell N. H. Inhibition of bcl‐2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara‐C. Leukaemia 1995; 9: 131–138
   PubMed Web of Science ®Google Scholar
• Campana D., Coustan‐Smith E., Manabe A., et al. Prolonged survival of B‐lineage acute lymphoblastic leukaemia cells is accompanied by overexpression of bcl‐2 protein. Blood 1993; 81: 1025–1031
   PubMed Web of Science ®Google Scholar
• Campos L., Rouault J. ‐P., Sabiolo O., et al. High expression of bcl‐2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Young I. T. Proof without prejudice: use of the Kolmogorov‐Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935–941
   PubMed Web of Science ®Google Scholar
• Danescu M., Rubio‐Trujillo M., Biron G., Dron D., Delespesse M., Scarfati M. Interleukin‐4 protects chronic lymphocytic leukaemic B cells from death by apoptosis and upregulates bcl‐2 expression. J Exp Med 1992; 176: 1319–1325
   PubMed Web of Science ®Google Scholar
• Rogers S. Y., Bradbury D., Kozlowski R., Russell N. H. Evidence for internal autocrine regulation of growth in acute myeloblastic leukaemia cells. Exp Haematol 1994; 22: 593–598
   PubMed Web of Science ®Google Scholar
• Bradbury D., Zhu Y. ‐M., Russell N. Regulation of bcl‐2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte‐macrophage colony‐stimulating factor. Leukemia. 1994; 8: 786–791
   PubMed Web of Science ®Google Scholar
• Reilly I. A. G., Kozlowski R., Russell N. H. Heterogenous mechanisms of autocrine growth of AML blasts. Br J Haematol 1989; 72: 363–369
   PubMed Web of Science ®Google Scholar
• Lowenberg B., van Potten W. L. J., Touw I., Dewel R., Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult myeloid leukaemia. New Engl J Med 1992; 328: 614–619
   Web of Science ®Google Scholar
• Hunter A. E., Rogers S. Y., Reilly I. A. G., Barrett A. J., Russell N. H. Autonomous growth of blast cels is associated with reduced survival in acute myeloblastic leukaemia. Blood 1993; 82: 899–903
   PubMed Web of Science ®Google Scholar
• Bradbury D., Rogers S., Reilly I. A. G., Kozlowski R., Russell N. H. Role of autocrine and paracrine production of granulocyte‐macrophage colony‐stimulating factor and interleukin‐l p in the autonomous growth of acute myeloblastic leukaemia cells—studies using purified CD34–positive cells. Leukaemia 1992; 6: 552–556
   Google Scholar
• Bradbury D., Rogers S., Kozlowski R., Bowen G., Reilly I. A. G., Russell N. H. Interleukin‐1 is one factor which regulates autocrine production of GM‐CSF by the blast cells of acute myeloblastic leukaemia. Br J Haematol 1990; 76: 488–493
   PubMed Web of Science ®Google Scholar
• Bradbury D., Bowen G., Kozlowski R., Reilly I. A. G., Russell N. H. Endogenous interleukin‐1 can regulate autonomous growth of acute myeloblastic leukaemia by inducing autocrine secretion of GM‐CSF. Leukemia 1990; 4: 44–47
   PubMed Web of Science ®Google Scholar
• Young D. C., Griffin J. D. Autocrine secretion of GM‐CSF in acute myeloblastic leukaemia. Blood 1986; 68: 1178–1181
   PubMed Web of Science ®Google Scholar
• Geller R. B., Zahurak M., Hurwitz C. A., et al. Prognostic importance of immunophenotyping in adults with acute myeloblastic leukaemia: the significance of stem cell glycoprotein CD34 (My lo). Br J Haematol 1990; 76: 340–347
   PubMed Web of Science ®Google Scholar
• Lee E. J., Yang J., Leavitt R. D., et al. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukaemia. Leukaemia 1992; 6: 1203–1209
   PubMed Web of Science ®Google Scholar
• te Boekhorst P. A. W., Lowenberg B., Sonneveld P. Enhanced chemosensitivity in acute myeloid leukaemia by haematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay. Leukaemia 1993; 7: 1637–1644
   PubMed Web of Science ®Google Scholar
• Selleri C., Notaro R., Catalano L., Fontana R., Vecchio L. D., Rotoli B. Prognostic irrelevance of CD34 in acute myeloid leukaemia. Br J Haematol 1992; 82: 479–480
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bareli M., Advani S. H., Benchimol S., Cline M. J. Alteration in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukaemia. PNAS USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Holmes J., Jacobs A., Carter G., Janowska‐Weiczorek A., Padua R. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 1989; 72: 40–44
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Regulation by bcl‐2, c‐myc and p53 of suseptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemic cells. Cell Growth Different 1993; 4: 41–47
   PubMedGoogle Scholar
• Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750–1757
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P. F., Kantarjian H., et al. Treatment of newly diagnosed acute myelogenous leukaemia with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) before and during continuous infusion high‐dose Ara‐C and daunorubicin: comparison to patients treated without GM‐CSF. Blood 1992; 79: 2246–2255
   PubMed Web of Science ®Google Scholar
• Hu Z. ‐B., Minden M. D., McCulloch E. A. Direct evidence for the participation of bcl‐2 in the regulation by retinoic acid of the Ara‐C sensitivity of leukaemic stem cells. Leukaemia 1995; 9: 1667–1673
   PubMed Web of Science ®Google Scholar